Search Results - "Cirstea, Diana D."

Regulation of Sclerostin Expression in Multiple Myeloma by Dkk‐1: A Potential Therapeutic Strategy for Myeloma Bone Disease by Eda, Homare, Santo, Loredana, Wein, Marc N, Hu, Dorothy Z, Cirstea, Diana D, Nemani, Neeharika, Tai, Yu‐Tzu, Raines, Sarah E, Kuhstoss, Stuart Allen, Munshi, Nikhil C, Kronenberg, Henry M, Raje, Noopur S

“…ABSTRACT Sclerostin is a potent inhibitor of osteoblastogenesis. Interestingly, newly diagnosed multiple myeloma (MM) patients have high levels of circulating…”
Get full text

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide by Yee, Andrew J., Hari, Parameswaran, Marcheselli, Raffaella, Mahindra, Anuj K., Cirstea, Diana D., Scullen, Tyler A., Burke, Jill N., Rodig, Scott J., Hideshima, Teru, Laubach, Jacob P., Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Anderson, Kenneth C., Weller, Edie A., Richardson, Paul G., Raje, Noopur S.

“…Summary Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has been studied in multiple myeloma (MM) but lacks significant single agent…”
Get full text

Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors by Chattopadhyay, Shrikanta, Stewart, Alison L., Mukherjee, Siddhartha, Huang, Cherrie, Hartwell, Kimberly A., Miller, Peter G., Subramanian, Radhika, Carmody, Leigh C., Yusuf, Rushdia Z., Sykes, David B., Paulk, Joshiawa, Vetere, Amedeo, Vallet, Sonia, Santo, Loredana, Cirstea, Diana D., Hideshima, Teru, Dančík, Vlado, Majireck, Max M., Hussain, Mahmud M., Singh, Shambhavi, Quiroz, Ryan, Iaconelli, Jonathan, Karmacharya, Rakesh, Tolliday, Nicola J., Clemons, Paul A., Moore, Malcolm A.S., Stern, Andrew M., Shamji, Alykhan F., Ebert, Benjamin L., Golub, Todd R., Raje, Noopur S., Scadden, David T., Schreiber, Stuart L.

“…Novel therapeutic approaches are urgently required for multiple myeloma (MM). We used a phenotypic screening approach using co-cultures of MM cells with bone…”
Get full text

Effect of the Pan-PIM Kinase Inhibitor, AZD1208, Alone and in Combination with Bortezomib in Multiple Myeloma by Santo, Loredana, Ramachandran, Janani, Cirstea, Diana D, Eda, Homare, Nemani, Neeharika, Hideshima, Teru, Dharminder, Chauhan, Huszar, Dennis, Anderson, Kenneth C., Raje, Noopur

“…The proto-oncogene proviral integration site for moloney murine leukemia virus (PIM) kinases (PIM-1, PIM-2, and PIM-3) are serine/threonine kinases upregulated…”
Get full text

Inhibition Of Autophagy By ACY-1215, a Selective HDAC6 Inhibitor Accelerates Carfilzomib-Induced Cell Death In Multiple Myeloma by Mishima, Yuko, Santo, Loredana, Cirstea, Diana D., Eda, Homare, Nemani, Neeharika, Arastu-Kapur, Shirin, Kirk, Christopher J., Jones, Simon S, Noopur, Raje

“…Proteasome inhibitors (PI) induce significant apoptosis associated with c-Jun NH2-terminal kinase (JNK) and caspase activation in multiple myeloma (MM). When…”
Get full text

Combinational Therapy of Lenalidomide with Activin A Neutralizing Antibody; Preclinical Rationale for a Novel Anti-Myeloma Strategy by Scullen, Tyler, Vallet, Sonia, Santo, Loredana, Fulciniti, Mariateresa, Eda, Homare, Cirstea, Diana D., Patel, Kishan, Yee, Andrew, Mahindra, Anuj, Raje, Noopur

“…Abstract 1871 Multiple myeloma (MM) is characterized by the vast majority of patients developing osteolytic bone lesions consequent to biochemical imbalances…”
Get full text

Increased Sclerostin Secretion in Multiple Myeloma Results in Stimulation of Osteoclastogenesis and Inhibition of Osteoblastogenesis by Eda, Homare, Santo, Loredana, Cirstea, Diana D., Pozzi, Samantha, Canavese, Miriam, Scullen, Tyler A., Vallet, Sonia, Raje, Noopur S.

“…Abstract 1819 Osteoblasts (OB) and osteoclasts (OC), are an integral part of the bone microenvironment, and play a crucial role in myeloma growth and survival…”
Get full text

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma by Suzuki, Rikio, Hideshima, Teru, Ohkubo, Shuichi, Mimura, Naoya, Minami, Jiro, Ohguchi, Hiroto, Kikuchi, Shohei, Cirstea, Diana D., Cottini, Francesca, Chauhan, Dharminder, Richardson, Paul G., Munshi, Nikhil C., Utsugi, Teruhiro, Anderson, Kenneth C.

“…Heat-shock protein 90 (HSP90) is a molecular chaperone considered to be attractive therapeutic target in many cancers, including multiple myeloma (MM), since…”
Get full text

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity by Eda, Homare, Santo, Loredana, Cirstea, Diana D, Yee, Andrew J, Scullen, Tyler A, Nemani, Neeharika, Mishima, Yuko, Arastu-Kapur, Shirin, Evans, Erica, Singh, Juswinder, Kirk, Christopher J, Westlin, William F, Raje, Noopur S

“…A member of the Tec family kinases, Bruton's tyrosine kinase (Btk) modulates B-cell development and activation, and plays an important role in antibody…”
Get full text

Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma by Eda, Homare, Santo, Loredana, Cirstea, Diana D., Pozzi, Samantha, Canavese, Miriam, Scullen, Tyler A., Vallet, Sonia, Evans, Erica, Singh, Juswinder, Raje, Noopur S.

“…Abstract 2882 Bone disease is a hallmark of multiple myeloma (MM) and targeting osteoclasts (OC) to alleviate bone destruction is a component of the standard…”
Get full text

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM) by Fabre, Claire, Mimura, Naoya, Bobb, Kathryn, Gorgun, Gullu, Cirstea, Diana D., Hu, Yiguo, Minami, Jiro, Ohguchi, Hiroto, Zhang, Jie, Meshulam, Jeffrey, Mitsiades, Constantine S., Richardson, Paul G., Hideshima, Teru, Anderson, Kenneth C.

“…Abstract 2902 NF-kB plays a crucial role in the pathogenesis of multiple myeloma (MM). In MM cells, NF-kB pathway is constitutively activated and regulates…”
Get full text

Niche-Based Screening Identifies Novel Small Molecules That Overcome Stromal Effects in Multiple Myeloma by Chattopadhyay, Shrikanta, Stewart, Alison L., Mukherjee, Siddhartha, Huang, Cherrie, Hartwell, Kimberly A., Miller, Peter G., Carmody, Leigh, Yusuf, Rushdia Z., Sykes, David B., Vallet, Sonia, Santo, Loredana, Cirstea, Diana D., Hideshima, Teru, Dancik, Vladimir, Cheah, Jaime, Price, Edmund, Bracha, Abigail, Majireck, Max, Hussain, Mahmud, Singh, Shambhavi, Tolliday, Nicola, Moore, Malcolm A.S., Stern, Andrew M., Shamji, Alykhan F, Ebert, Benjamin L., Golub, Todd R., Raje, Noopur, Scadden, David T., Schreiber, Stuart L.

“…Abstract 571 Despite advances in the treatment of multiple myeloma (MM), this disease remains incurable and novel therapeutic strategies are urgently needed…”
Get full text

Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide by Yee, Andrew J., Mahindra, Anuj K., Richardson, Paul G., Cirstea, Diana D., Scullen, Tyler A., Rodig, Scott J., Hideshima, Teru, Hari, Parameswaran, Laubach, Jacob P., Ghobrial, Irene M., Schlossman, Robert, Munshi, Nikhil C., Weller, Edie A., Anderson, Kenneth C., Raje, Noopur S.

“…Abstract 3966 Lenalidomide plus dexamethasone is approved for the treatment of relapsed and/or refractory multiple myeloma following prior therapy. Everolimus,…”
Get full text

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma by Mimura, Naoya, Fulciniti, Mariateresa, Gorgun, Gullu, Tai, Yu-Tzu, Cirstea, Diana D., Santo, Loredana, Hu, Yiguo, Fabre, Claire, Minami, Jiro, Ohguchi, Hiroto, Kiziltepe, Tanyel, Ikeda, Hiroshi, Kawano, Yutaka, Blumenthal, Martina, Tam, Victor, Kertesz, Nathalie L., Hokenson, Mark, Zeng, Qingping, Patterson, John B., Richardson, Paul G., Munshi, Nikhil C., Anderson, Kenneth C.

“…Abstract 133 Multiple myeloma (MM) cells are characterized by high protein synthesis resulting in chronic endoplasmic reticulum (ER) stress, which is…”
Get full text

Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma by Santo, Loredana, Hideshima, Teru, Kung, Andrew L., Tseng, Jen-Chieh, Tamang, David, Yang, Min, Jarpe, Matthew, van Duzer, John H., Mazitschek, Ralph, Ogier, Walter C, Cirstea, Diana D., Rodig, Scott, Eda, Homare, Scullen, Tyler A., Canavese, Miriam, Bradner, James E., Anderson, Kenneth C, Jones, Simon, Raje, Noopur S.

“…Abstract 2912 HDAC enzymes are being studied as novel therapeutic targets in several cancers including multiple myeloma (MM). In particular, the combination of…”
Get full text